173 related articles for article (PubMed ID: 32338093)
1. Discovery of 5-methyl-
Im D; Moon H; Kim J; Oh Y; Jang M; Hah JM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1110-1115. PubMed ID: 32338093
[TBL] [Abstract][Full Text] [Related]
2. Conformational restriction of a type II FMS inhibitor leading to discovery of 5-methyl-
Im D; Moon H; Kim J; Oh Y; Jang M; Hah JM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1716-1721. PubMed ID: 31571509
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
Im D; Jung K; Yang S; Aman W; Hah JM
Eur J Med Chem; 2015 Sep; 102():600-10. PubMed ID: 26318067
[TBL] [Abstract][Full Text] [Related]
4. Rational design and synthesis of 2-(1
Im D; Jun J; Baek J; Kim H; Kang D; Bae H; Cho H; Hah JM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):472-486. PubMed ID: 35067150
[TBL] [Abstract][Full Text] [Related]
5. Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.
Chen Y; Bai G; Li Y; Ning Y; Cao S; Zhou J; Ding J; Zhang H; Xie H; Duan W
Bioorg Med Chem; 2021 Oct; 48():116422. PubMed ID: 34583130
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
[TBL] [Abstract][Full Text] [Related]
9. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
[TBL] [Abstract][Full Text] [Related]
10. Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations.
Zhang G; Zhang W; Shen C; Nan J; Chen M; Lai S; Zhong J; Li B; Wang T; Wang Y; Yang S; Li L
Bioorg Med Chem Lett; 2020 Nov; 30(22):127532. PubMed ID: 32891702
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.
Lin XD; Yang HW; Ma S; Li WW; Zhang CH; Wang WJ; Xiang R; Li LL; Yang SY
Bioorg Med Chem Lett; 2015 Oct; 25(20):4534-8. PubMed ID: 26342867
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.
Wang A; Li X; Chen C; Wu H; Qi Z; Hu C; Yu K; Wu J; Liu J; Liu X; Hu Z; Wang W; Wang W; Wang W; Wang L; Wang B; Liu Q; Li L; Ge J; Ren T; Zhang S; Xia R; Liu J; Liu Q
J Med Chem; 2017 Oct; 60(20):8407-8424. PubMed ID: 28956923
[TBL] [Abstract][Full Text] [Related]
15. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
16. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
18. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsieh SY; Yen SC; Chen CT; Yeh TK; Hsu T; Lu CT; Chen CP; Chen CW; Chou LH; Huang YL; Cheng AH; Chang YI; Tseng YJ; Yen KR; Chao YS; Hsu JT; Jiaang WT
Bioorg Med Chem; 2011 Jul; 19(14):4173-82. PubMed ID: 21708468
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N
Gucký T; Řezníčková E; Radošová Muchová T; Jorda R; Klejová Z; Malínková V; Berka K; Bazgier V; Ajani H; Lepšík M; Divoký V; Kryštof V
J Med Chem; 2018 May; 61(9):3855-3869. PubMed ID: 29672049
[TBL] [Abstract][Full Text] [Related]
20. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
